Crossmark

A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau

Crossref DOI link: https://doi.org/10.14283/jpad.2024.25

Published Print: 2024-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Luca, Wendy

Foster, K.

McClure, K.

Ahlijanian, M.K.

Jefson, M.
License Information

Text and Data Mining valid from 2024-03-01

Text and Data Mining valid from 2024-03-01

Version of Record valid from 2024-01-24
More Information

This article is maintained by: Elsevier

Article Title: A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau

Journal Title: The Journal of Prevention of Alzheimer's Disease

CrossRef DOI link to publisher maintained version: https://doi.org/10.14283/jpad.2024.25

Content Type: article

Copyright: Copyright © 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS

Document is current

Any future updates will be listed below